[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
- PMID: 7989493
- DOI: 10.1210/jcem.79.6.7989493
[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Abstract
Visualization of malignant lymphomas and granulomatous disease is possible by [111In-DTPA-D-Phe1]octreotide scintigraphy through binding of the radioligand to somatostatin receptors on activated leukocytes. Because thyroidal and orbital tissues are infiltrated by activated leukocytes in Graves' disease, a cross-sectional study to visualize disease activity with [111In-DTPA-D-Phe1]octreotide scintigraphy was performed. A correlation between thyroidal [111In-DTPA-D-Phe1]octreotide accumulation and free T4 (disease expression) and thyroid binding-inhibiting immunoglobulins (disease activity) is present in untreated hyperthyroid Graves' disease. There is also a correlation between orbital [111In-DTPA-D-Phe1]octreotide uptake and the clinical activity score (disease activity) and total eye score (disease expression), respectively, in Graves' orbitopathy. Visualization of thyroidal and orbital Graves' disease is feasible, but further investigation is necessary to establish the role of [111In-DTPA-D-Phe1]octreotide scintigraphy in representing disease activity and expression and in predicting therapeutical outcome.
Similar articles
-
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.J Clin Endocrinol Metab. 1998 Nov;83(11):3790-4. doi: 10.1210/jcem.83.11.5274. J Clin Endocrinol Metab. 1998. PMID: 9814448 Clinical Trial.
-
Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.J Clin Endocrinol Metab. 2005 Apr;90(4):2440-4. doi: 10.1210/jc.2004-2135. Epub 2005 Feb 1. J Clin Endocrinol Metab. 2005. PMID: 15687327
-
A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.Eur J Nucl Med. 1994 Apr;21(4):328-35. Eur J Nucl Med. 1994. PMID: 7911760
-
Octreotide scintigraphy in thyroidal and orbital Graves' disease.Thyroid. 1998 May;8(5):433-6. doi: 10.1089/thy.1998.8.433. Thyroid. 1998. PMID: 9623738 Review. No abstract available.
-
Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.Eur Radiol. 1997;7(7):1103-9. doi: 10.1007/s003300050262. Eur Radiol. 1997. PMID: 9265684 Review.
Cited by
-
Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.J Endocrinol Invest. 2006 May;29(5):413-22. doi: 10.1007/BF03344124. J Endocrinol Invest. 2006. PMID: 16794364 Clinical Trial.
-
[Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].Ophthalmologe. 2003 Dec;100(12):1049-53. doi: 10.1007/s00347-003-0807-1. Ophthalmologe. 2003. PMID: 14704818 German.
-
99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study.Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2286-93. doi: 10.1007/s00259-008-0837-7. Epub 2008 Jun 10. Eur J Nucl Med Mol Imaging. 2008. PMID: 18542959 Clinical Trial.
-
Update on advanced imaging options for thyroid-associated orbitopathy.Saudi J Ophthalmol. 2012 Oct;26(4):385-92. doi: 10.1016/j.sjopt.2012.07.006. Saudi J Ophthalmol. 2012. PMID: 23961023 Free PMC article.
-
(99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).Endocrine. 2007 Jun;31(3):305-10. doi: 10.1007/s12020-007-0039-2. Endocrine. 2007. PMID: 17906380 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical